Evidence-Based Research

Dr. Johnson was granted several US patents related to the biological function of protocatechuate; a.k.a protocatechuic acid (PCA).  PCA is the primary metabolite from the dyes that make blueberries blue and cherries red.  When one eats those fruits the dyes are rapidly and completely metabolized into PCA and absorbed into your blood steam.  However, the amount possible by diet is far less than that which would have a significant biological effect.  For instance, one would have to eat 18 pounds of blueberries, at once to have a therapeutic effect on the body.

However, when isolated in the pure concentrated form, protocatechuate has certain beneficial biological properties as established by the supporting evidence published in the following patents.

As a result of several years research in the laboratory and the clinic, the formulation of A-Cosmetic was discovered.  This research included a two-year, four-phase study human study at Loma Linda Medical School looking for a pre-operative disinfectant.  The effectiveness of the A-Cosmetic formulation was established with the potential to disinfect human skin of many potential pathogens, including Propionibacterium acnes.  These discoveries have resulted in several United States patents (view specific patent claims below).

Patents

The following patents are in this portfolio as of August 31, 2021.  The specific claims of each may be view under the patent number at https://patft.uspto.gov/netahtml/PTO/srchnum.htm

September 11, 2012.  This patent showed that the dyes of plants (anthocyanins and anthocyanins) the precursor of the metabolite protocatechuic acid turned on the gene for growth hormone IGF-1 in human synovium.

November 8, 2016.  This patent secured the intra articular injection route not previously included in the granted patent claims for cyanidin-3-glucoside.

November 22, 2016.  This was the parent patent showing broad spectrum antibiotic properties and wound healing acceleration.  See the illustrations above.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

May 15, 2018.  This patent secures that protocatechuic acid can only be manufactured and delivered to an end user by the owner of this patent.

 

June 5, 2018.  This patent was a continuation of 9,925,152 that now allowed for intra-articular injection.

July 26, 2018.  This patent included the metabolites of protocatechuic acid and 2,4,6 trihydroxybenzaldehyde for the destruction of biofilms of MRSA and Pseudomonas on metal, cloth and ceramic.

July 26, 2018.  This was an expansion of 10,004,705 applications.

July 10, 2018. This patent expanded the formulation for treatment of implants to include protocatechuic acid, 70% isopropyl alcohol, propylene glycol, and an essential oil.

July 31, 2018. This patent includes the chemical formulation of 10,016,380 for medical and surgical implants, dental implants and instrumentation.  The later for spaying or soaking in solution.

December 4, 2018. This patent secures the use of PCA to  coat a bandage or dressing at time or treatment and or a commercial preparation for as stated in claim #22 if a wound is a burn, skin break, bone break, muscle tear, puncture, surgical incision site, microdermabrasion site, skin graft site, a wound associated with diabetes, a bed sore, a pressure sore, skin defoliation, or a laceration, and wherein the protocatechuic acid becomes activated by contact with moisture from the wound.

April 23, 2019. An extension of prior claims that specifically cite PCA as an antibacterial for Propionibacterium acnes.  This for the treatment of skin acne.

May 21, 2019.   This patent extends the use of PCA to the food industry.

September 3, 2019. This is a non-surgical method of loosening biofilms from an implant via ultrasound and then treating without surgery.  The treatment would be repeated needle aspirations for infection status and then injection of protocatechuic acid crystals to destroy the biofilms attached to the implant.

October 1, 2019. This is an extension and further specification of the skin penetration formulation claims for pre-operative skin disinfection and facial acne with concentration above 10%.

September 5, 2020.  This is an extension that includes the disinfectant and sanitizer use emphasizing the residual anti-microbial protocatechuic acid coating the remains on the article and or person after the evaporation of the liquid vehicle.

 

March 30, 2021.  The treatment of COVID19 virus with protocatechuic acid.  This patent is for treating the patient; oral, intravenous, injection, etc.  Working toward regulations approvals.

August 31, 2021.  Anti-microbials and the Methods and Use thereof. This patent is for mitigation of bacteria and virus (COVID 19) by coating of personal protective equipment; masks, gowns, hats, shoes, etc.

Listing of the claims as they actually appear on the patient related to A-Cosmetic product:

12. A method for inhibiting P. acnes growth on mammalian skin tissue, comprising: applying a liquid composition to the skin tissue, the composition comprising  about 10% or more of protocatechuic acid (PCA), and a liquid carrier comprising 70% to 91% grade isopropyl alcohol, wherein commensal microorganisms are preserved.

13. The method according to claim 12, wherein the PCA is present at a concentration of from about 10% to about 50% by weight of the composition.

14. The method according to claim 12, wherein the liquid composition further comprises propylene glycol and an essential oil, wherein the components all possess anti-bacterial and skin penetration properties.

15. The method according to claim 12, wherein the amount of PCA is from about 10% to about 30% by weight of the composition.

16. The method according to claim 12, wherein the liquid composition comprises: about 1% to about 15% propylene glycol and about 1% to about 5% of an essential oil, by weight of the composition.

17-20. (Cancelled) 

21. The method according to claim 12, wherein the PCA is administered in an amount of about 60 mg/kg.

22. The method according to claim 12, wherein the mammal is a human.

23. The method according to claim 12, wherein the composition comprises about 10% PCA.

24. The method according to claim 12, wherein the composition comprises about 17% PCA.

25. The method according to claim 12, wherein the composition comprises about 20% PCA.

26. The method according to claim 12, wherein the liquid carrier comprises 70% grade isopropyl alcohol.

27. The method according to claim 12, wherein the liquid carrier comprises 91% grade isopropyl alcohol.